UA112752C2 - Лікарський засіб та метод блокування утворення або посилення знищення білка p24 - Google Patents
Лікарський засіб та метод блокування утворення або посилення знищення білка p24Info
- Publication number
- UA112752C2 UA112752C2 UAA201300111A UAA201300111A UA112752C2 UA 112752 C2 UA112752 C2 UA 112752C2 UA A201300111 A UAA201300111 A UA A201300111A UA A201300111 A UAA201300111 A UA A201300111A UA 112752 C2 UA112752 C2 UA 112752C2
- Authority
- UA
- Ukraine
- Prior art keywords
- seq
- protein
- pharmaceutical composition
- receptor
- amplifying
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000008030 elimination Effects 0.000 title 1
- 238000003379 elimination reaction Methods 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 108010041397 CD4 Antigens Proteins 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 239000012895 dilution Substances 0.000 abstract 1
- 238000010790 dilution Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000001632 homeopathic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Alternative & Traditional Medicine (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2010133046/15A RU2517084C2 (ru) | 2010-08-06 | 2010-08-06 | Способ и средство для ингибирования продукции или усиления элиминации белка р24 |
| PCT/IB2011/002355 WO2012017322A2 (en) | 2010-08-06 | 2011-07-15 | Pharmaceutical composition and method of inhibiting of production or amplifying elimination of p24 protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA112752C2 true UA112752C2 (uk) | 2016-10-25 |
Family
ID=44899160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201300111A UA112752C2 (uk) | 2010-08-06 | 2011-07-15 | Лікарський засіб та метод блокування утворення або посилення знищення білка p24 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20120263726A1 (enExample) |
| JP (1) | JP2013535483A (enExample) |
| CN (1) | CN103179987A (enExample) |
| AU (1) | AU2011287286A1 (enExample) |
| CA (1) | CA2807523A1 (enExample) |
| DE (1) | DE112011102639T5 (enExample) |
| EA (1) | EA029791B1 (enExample) |
| ES (1) | ES2415029R1 (enExample) |
| GB (1) | GB2496356A (enExample) |
| IT (1) | ITTO20110636A1 (enExample) |
| MX (1) | MX2013001450A (enExample) |
| PH (1) | PH12013500233A1 (enExample) |
| RU (1) | RU2517084C2 (enExample) |
| SG (1) | SG187735A1 (enExample) |
| UA (1) | UA112752C2 (enExample) |
| WO (1) | WO2012017322A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2181297C2 (ru) | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
| RU2309732C1 (ru) * | 2006-03-13 | 2007-11-10 | Олег Ильич Эпштейн | Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата |
| MX2013000543A (es) | 2010-07-15 | 2013-10-28 | Oleg Iliich Epshtein | Un metodo para aumentar el efecto de una forma activa potenciada de un anticuerpo. |
| FR2962652A1 (fr) | 2010-07-15 | 2012-01-20 | Oleg Iliich Epshtein | Composition pharmaceutique d'association et son utilisation dans des procedes pour traiter les maladies ou affections associees a des maladies neurodegeneratives |
| PH12013500144A1 (en) | 2010-07-21 | 2018-03-21 | Oleg Iliich Epshtein | A method of treating attention deficit hyperactivity disorder |
| RU2013111961A (ru) | 2013-03-18 | 2014-09-27 | Олег Ильич Эпштейн | Способ определения выраженности модифицирующей активности, ассоциированной с носителем |
| RU2013111962A (ru) | 2013-03-18 | 2014-09-27 | Олег Ильич Эпштейн | Способ определения выраженности модифицирующей активности, ассоциированной с носителем |
| RU2603623C2 (ru) * | 2014-06-06 | 2016-11-27 | Олег Ильич Эпштейн | Ветеринарная композиция и способ улучшения жизнеспособности животных, стимуляции прироста живой массы млекопитающих и птиц, повышения эффективности иммунизации, профилактики и/или лечения инфекционных заболеваний (варианты) |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4311897A (en) | 1979-08-28 | 1982-01-19 | Union Carbide Corporation | Plasma arc torch and nozzle assembly |
| DE4236069A1 (de) * | 1992-10-26 | 1994-04-28 | Werner Dr Bergmann | Arzneimittel, insbesondere für orale Einnahme |
| US5567604A (en) * | 1993-04-23 | 1996-10-22 | Aronex Pharmaceuticals, Inc. | Anti-viral guanosine-rich oligonucleotides |
| CA2268372C (en) * | 1996-10-10 | 2012-11-27 | Probe International | Compositions and methods for treating viral infections |
| AU6941000A (en) * | 1999-08-27 | 2001-03-26 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Polypeptides that bind hiv gp120 and related nucleic acids, antibodies, compositions, and methods of use |
| WO2001043779A2 (en) * | 1999-12-16 | 2001-06-21 | Tanox, Inc. | Anti-hiv-1 conjugates for treatment of hiv disease |
| RU2181297C2 (ru) * | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
| RU2001134982A (ru) * | 2001-12-26 | 2004-02-20 | Олег Ильич Эпштейн | Способ коррекции иммунного ответа и лекарственное средство |
| AU2003246119B2 (en) * | 2002-06-28 | 2008-02-21 | Fuso Pharmaceutical Industries, Ltd. | Anti-HIV agent |
| UA76641C2 (uk) | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози |
| UA76638C2 (en) | 2002-08-02 | 2006-08-15 | Oleh Illich Epshtein | Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon |
| AP2005003294A0 (en) * | 2002-09-27 | 2005-06-30 | Tanox Inc | Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome |
| GB2414670B (en) | 2003-03-14 | 2008-03-19 | Nutrition Res Inc | Homeopathic formulations useful for treating pain and/or inflammation |
| RU2393873C2 (ru) * | 2005-05-02 | 2010-07-10 | Майметикс Корпорейшн | Антитело или его фрагмент, имеющие нейтрализующую активность в отношении вич, но не в отношении il2 |
| RU2315058C1 (ru) * | 2006-09-27 | 2008-01-20 | Институт органической химии Уфимского научного центра РАН | Гликопептид глицирризиновой кислоты с глицил-l-фенилаланином, проявляющий анти-вич-1 активность |
| US20120263725A1 (en) * | 2010-08-06 | 2012-10-18 | Epshtein Oleg Iiiich | Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV |
-
2010
- 2010-08-06 RU RU2010133046/15A patent/RU2517084C2/ru not_active IP Right Cessation
-
2011
- 2011-07-15 EA EA201300138A patent/EA029791B1/ru not_active IP Right Cessation
- 2011-07-15 UA UAA201300111A patent/UA112752C2/uk unknown
- 2011-07-15 SG SG2013009022A patent/SG187735A1/en unknown
- 2011-07-15 ES ES201390020A patent/ES2415029R1/es active Pending
- 2011-07-15 CN CN2011800388401A patent/CN103179987A/zh active Pending
- 2011-07-15 US US13/135,897 patent/US20120263726A1/en not_active Abandoned
- 2011-07-15 WO PCT/IB2011/002355 patent/WO2012017322A2/en not_active Ceased
- 2011-07-15 PH PH1/2013/500233A patent/PH12013500233A1/en unknown
- 2011-07-15 IT IT000636A patent/ITTO20110636A1/it unknown
- 2011-07-15 JP JP2013522317A patent/JP2013535483A/ja active Pending
- 2011-07-15 GB GB1303865.8A patent/GB2496356A/en not_active Withdrawn
- 2011-07-15 CA CA2807523A patent/CA2807523A1/en not_active Abandoned
- 2011-07-15 AU AU2011287286A patent/AU2011287286A1/en not_active Abandoned
- 2011-07-15 DE DE112011102639T patent/DE112011102639T5/de not_active Withdrawn
- 2011-07-15 MX MX2013001450A patent/MX2013001450A/es unknown
-
2013
- 2013-05-15 US US13/894,476 patent/US20130315964A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2415029R1 (es) | 2013-09-17 |
| US20130315964A1 (en) | 2013-11-28 |
| MX2013001450A (es) | 2013-10-25 |
| US20120263726A1 (en) | 2012-10-18 |
| WO2012017322A3 (en) | 2012-04-19 |
| WO2012017322A2 (en) | 2012-02-09 |
| EA201300138A1 (ru) | 2014-03-31 |
| RU2010133046A (ru) | 2012-02-20 |
| SG187735A1 (en) | 2013-03-28 |
| GB2496356A (en) | 2013-05-08 |
| AU2011287286A1 (en) | 2013-03-14 |
| ES2415029A2 (es) | 2013-07-23 |
| CN103179987A (zh) | 2013-06-26 |
| RU2517084C2 (ru) | 2014-05-27 |
| CA2807523A1 (en) | 2012-02-09 |
| GB201303865D0 (en) | 2013-04-17 |
| EA029791B1 (ru) | 2018-05-31 |
| JP2013535483A (ja) | 2013-09-12 |
| ES2415029A8 (es) | 2013-09-16 |
| PH12013500233A1 (en) | 2017-08-23 |
| DE112011102639T5 (de) | 2013-10-02 |
| ITTO20110636A1 (it) | 2012-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA112752C2 (uk) | Лікарський засіб та метод блокування утворення або посилення знищення білка p24 | |
| WO2007095318A3 (en) | Influenza antigens, vaccine compositions, and related methods | |
| EA201000018A1 (ru) | Лиофилизированные лекарственные формы иммуноглобулинов и способы их получения | |
| MX2014001372A (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico. | |
| AR081434A1 (es) | Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo | |
| EA201201305A1 (ru) | Композиция опухолеассоциированных пептидов и относящаяся к ним противораковая вакцина для лечения рака желудка и других видов рака | |
| PE20241623A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| MY155400A (en) | Anti cxcr4 antibodies for the treatment of hiv | |
| NI201500024A (es) | Anticuerpos y vacunas para utilizarse en el tratamiento de cánceres por ror1 y para inhibir la metástasis. | |
| EA201391613A8 (ru) | КОМПОЗИЦИЯ АНТИ-α4β7 АНТИТЕЛА | |
| MX2016002937A (es) | Vacuna oncologica. | |
| EA201391719A1 (ru) | Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний | |
| AR082314A1 (es) | Una composicion farmaceutica de combinacion para el tratamiento de vertigo, cinetosis y distonia vegetativa vascular | |
| WO2008134643A3 (en) | Trypanosoma antigens, vaccine compositions, and related methods | |
| PE20131185A1 (es) | Composicion farmaceutica combinada y metodos para el tratamiento y prevencion de las enfermedades infecciosas | |
| IN2014KN01713A (enExample) | ||
| EA201291067A1 (ru) | Гуманизированные антигенсвязывающие белки к миостатину | |
| AR082246A1 (es) | Composicion farmaceutica de anticuerpo a receptor cannabinoide humano | |
| MX2013009151A (es) | Inmunoterapia mejorada. | |
| EA201170954A1 (ru) | Фармацевтический или пищевой состав с контролируемым высвобождением и способ его получения | |
| EA201691836A1 (ru) | Антитела к mcam и соответствующие способы их применения | |
| JP2013535483A5 (enExample) | ||
| EA201300132A1 (ru) | Фармацевтическая композиция и методы лечения и профилактики заболеваний, вызванных вич или ассоциированных с вич | |
| JP2013535445A5 (enExample) | ||
| UA112755C2 (uk) | Метод лікування синдрому дефіциту уваги і гіперактивності |